Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).
Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).
Transfection Reagent for COLO-205 Cells (Colon Adenocarcinoma Cell, CCL-222)
A nanoparticle-based liposome formulation
Transfection protocols provided for transfection of proteins, DNA, mRNA, siRNA, shRNA and microRNA
Produce higher level of recombinant protein expression with minimal disruption of normal cell function
Generate physiologically relevant data you can trust
Effective for plasmid DNA/siRNA co-transfection
Easy-to-use transfection protocol with reproducible results
- Download COLO205 CRISPR/Cas9 transfection protocol: [PDF]
Download PowerPoint presentation for COLO-205 cells transfection kit: [PPT]
Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 91% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems COLO-205 Transfection Protocol: [PDF]
Download MSDS: [PDF]
COLO-205 Cell Line:
Colon cancer is the third most prevalent cancer globally and the second primary cause of cancer-related deaths that is reportedly responsible for more than 50,000 fatalities every year in the United States alone. The lifetime risk of developing colon cancer is slightly lower in women than in men, as stated by the American Cancer Society (ACS). The COLO-205 cell line was established in 1975 from a 70-year-old Caucasian male patient with colon cancer. These cells exhibit epithelial cell morphology and come from a Dukes’ type D tumor. The patient had been treated with 5-fluorouracil for approximately five weeks before removal of the specimen. Also, the cells have been tested negative for CSAp, positive for keratin, and express a 36,000-dalton cell surface glycoprotein, which has a related antigen. The COLO-205 cell line is similar to COLO 201 and was derived from the same patient. In addition to being an adequate host for studying colon cancer, this cell line is utilized for researching the SV-40 monkey virus. Moreover, in biochemistry, the COLO-205 cell line is used for transfection and has applications for the production of recombinant proteins. Altogen Biosystems provides transfection reagent kits for the COLO-205 colon cancer cell line. The nanoparticle-based reagents have demonstrated high efficiency and low cytotoxicity.
Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into COLO-205 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).
Figure 2. Protein expression of Lamin A/C in COLO-205 cells. DNA plasmid expressing Lamin A/C or siRNA targeting Lamin A/C were transfected into COLO-205 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems provides preoptimized transfection products for life science research applications. Transfection protocols are optimized for individual cancer cell lines. Altogen Biosystems developed two types of in vivo delivery kits for animal research: Tissue-targeted reagents (delivery to liver, pancreas, and kidney tissues), and broad range in vivo delivery reagents (PEG-Liposome, Nanoparticle-based, Lipid-based, and Polymer-based kits). Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, RNA, and any other negatively charged molecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Contract Research Services:
Altogen Labs provides good laboratory practice (GLP) compliant preclinical research services for IND applications and drug development. Our biology CRO services includes both efficacy studies (over 90 in-house validated xenograft models) and safety pharmacology/toxicology studies (for more details please visit AltogenLabs.com).
- 0.5 ml (Catalog #6452)
- 1.5 ml (Catalog #6453)
- 1.5 ml CRISPR (Catalog #2132)
- 8.0 ml (Catalog #7032)